The Effect of CYP2D6 Polymorphisms on the Response to Pain Treatment for Pediatric Sickle Cell Pain Crisis

Journal of Pediatrics

Volumn 150, Issue 6, 2007, Pages 623-626

  Brousseau, David C ^a   McCarver, D Gail ^a   Drendel, Amy L ^a   Divakaran, Karthika ^a   Panepinto, Julie A ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CODEINE; CYTOCHROME P450 2D6; HYDROXYUREA; PARACETAMOL;

ALLELE; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE SEVERITY; EMERGENCY WARD; ENZYME ACTIVITY; ENZYME POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; SCORING SYSTEM; SICKLE CELL CRISIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ANALGESICS, OPIOID; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; CHILD; CHILD, PRESCHOOL; CODEINE; CYTOCHROME P-450 CYP2D6; GENE DELETION; GENOTYPE; HUMANS; HYDROXYUREA; PAIN; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 34248530257     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2007.01.049     Document Type: Article

References (24)

1. Platt O.S., Thorington B.D., Brambilla D.J., Milner P.F., Rosse W.F., Vichinsky E., et al. Pain in sickle cell disease: rates and risk factors. N Engl J Med 325 (1991) 11-16
2. Panepinto J.A., O'Mahar K.M., DeBaun M.R., Loberiza F.R., and Scott J.P. Health-related quality of life in children with sickle cell disease: child and parent perception. Br J Haematol 130 (2005) 437-444
3. Scott J.P., Hillery C.A., Brown E.R., Misiewicz V., and Labotka R.J. Hydroxyurea therapy in children severely affected with sickle cell disease. J Pediatr 128 (1996) 820-828
4. Charache S., Terrin M.L., Moore R.D., Dover G.J., Barton F.B., Eckert S.V., et al., Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 332 (1995) 1317-1322
5. Taylor J.G., Tang D.C., Savage S.A., Leitman S.F., Heller S.I., Serjeant G.R., et al. Variants in the VCAM1 gene and risk for symptomatic stroke in sickle cell disease. Blood 100 (2002) 4303-4309
6. Hoppe C., Cheng S., Grow M., Silbergleit A., Klitz W., Trachtenberg E., et al. A novel multilocus genotyping assay to identify genetic predictors of stroke in sickle cell anaemia. Br J Haematol 114 (2001) 718-720
7. Sullivan K.J., Kissoon N., Duckworth L.J., Sandler E., Freeman B., Bayne E., et al. Low exhaled nitric oxide and a polymorphism in the NOS I gene is associated with acute chest syndrome. Am J Respir Crit Care Med 164 (2001) 2186-2190
8. Passon R.G., Howard T.A., Zimmerman S.A., Schultz W.H., and Ware R.E. Influence of bilirubin uridine diphosphate-glucuronosyltransferase 1A promoter polymorphisms on serum bilirubin levels and cholelithiasis in children with sickle cell anemia. J Pediatr Hematol Oncol 23 (2001) 448-451
9. Wuttke H., Rau T., Heidi R., Bergmann K., Bohm M., Weil J., et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse events. Clin Pharmacol Ther 72 (2002) 429-437
10. Weinshilboum R. Inheritance and drug response. N Engl J Med 348 (2003) 529-537
11. Evans W., and McLeod H. Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med 348 (2003) 538-549
12. Bradford L. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3 (2002) 229-243
13. Gaedigk A., Bradford L., Marcucci K., and Leeder J. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther 72 (2002) 76-89
14. Wan Y.-J., Poland R., and Han G. Analysis of CYP2D6 polymorphism and enzyme activity in African-Americans in Southen California. Pharmacogenetics 11 (2001) 489-499
15. Eckhardt K., Li S., Ammon S., Schanzle G., Mikus G., and Eichelbaum M. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain 76 (1998) 27-33
16. Poulsen L., Brosen K., Arendt-Nielsen L., Gram L.F., Elbaek K., and Sindrup S.H. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol 51 (1996) 289-295
17. Caraco Y., Sheller J., and Wood A.J. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions. J Pharmacol Exp Ther 278 (1996) 1165-1174
18. http://www.imm.ki.se/CYPalleles/cyp2D6.htm. Accessed October 25, 2006.
19. Gaedigk A., Gotschall R., Forbes N., Simon S., Kearns G., and Leeder J. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics 9 (1999) 669-682
20. Findling R.L., Nucci G., Piergies A.A., Gomeni R., Bartolic E.I., Fong R., et al. Multiple-dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder. Neuropsychopharmacology 31 (2005) 1274-1285
21. Zineh I., Beitelshees A.L., Gaedigk A., Walker J.R., Pauly D.F., Eberst K., et al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther 76 (2004) 536-544
22. Tirkkonen T., and Laine K. Drug interactions with the potential to prevent prodrug activation as a common source of irrational prescribing in hospital inpatients. Clin Pharmacol Ther 76 (2004) 639-647
23. Platt O.S., Brambilla D.J., Rosse W.F., Milner P.F., Castro O., Steinberg M.H., et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med 330 (1994) 1639-1644
24. Gladwin M.T., Sachdev V., Jison M.L., Shizukuda Y., Plehn J.F., Minter K., et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 350 (2004) 886-895